成人1型糖尿病患者使用Omnipod DASH的治疗满意度:一项非盲1:1随机对照试验
该研究在澳大利亚4个糖尿病中心将使用每日多次注射或管式胰岛素泵治疗的成人1型糖尿病患者按1:1非盲随机分配至Omnipod DASH系统组或继续常规治疗组,干预12周。结果显示Omnipod组治疗满意度改善优于常规治疗组,其他患者报告结局和糖化血红蛋白也有改善,且改善在24周设备使用后得以维持。
要点
- Omnipod组12周时DTQ-current评分变化为16.4(21.2),常规治疗组为0.0(12.8),组间差异P < .001。
- 其他患者报告结局和糖化血红蛋白也观察到显著更大改善。
- 研究结束时血糖范围内时间百分比变化无差异(-2.0 [12.7]%),扩展期结束时Omnipod组改善显著更大(5.6 [10.9]%;P = .016)。
核心结论
- 在自我血糖监测的成人1型糖尿病患者中,Omnipod DASH系统在12周时带来更大的治疗满意度,且在24周设备使用后得以维持,未损害睡眠质量和低血糖恐惧,血糖控制也有改善。
研究设计与样本
- 来自澳大利亚4个糖尿病中心的成人1型糖尿病患者,使用每日多次注射(n = 40)或管式胰岛素泵(n = 25),按1:1非盲随机分配至Omnipod DASH系统组或继续常规治疗组,为期12周,随后进行进一步12周扩展期,期间所有参与者均使用该设备。
主要发现
- 研究结束时,Omnipod组治疗满意度改善大于常规治疗组(DTQ-current评分变化16.4 [21.2] vs 0.0 [12.8];P < .001)。
- 其他患者报告结局和糖化血红蛋白也观察到显著更大改善。
- 研究结束时血糖范围内时间百分比变化无差异(-2.0 [12.7]%),扩展期结束时Omnipod组改善显著更大(5.6 [10.9]%;P = .016)。
- 比较研究结束和扩展期结束时,DTQ-current和其他患者报告结局的改善相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). OBJECTIVE: We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). METHODS: Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire "current" (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). RESULTS: Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (-2.0 [12.7] %), it was significantly greater at end extension (5.6 [10.9] %; P = .016). CONCLUSION: The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.
引用
- Kong YW, Yuan CY, Kiburg K, et al. Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial. J Clin Endocrinol Metab. 2024. PMID: 38373265. doi:10.1210/clinem/dgae088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。